The market is making a huge mistake right now, in our view. But as an investor, I WELCOME this grave misjudgment on the part of other investors; we’re getting a rare chance, a 2^nd entry point to ride a potential rally with KOIOS Beverages (CSE: KBEV & US: KBEVF).

I’m not the only one seeing this potential anomaly in correctly pricing the true value of this company. Aussie Jiwani, who was Key Account Manager for BC Retail Chains and Grocery for Arterra Wines Canada (formerly Constellation Brands Canada); and former National Account Manager with Molson Coors Canada – the largest beer producer in the country –has just joined the company’s advisory board. He comes with 23 years of experience in the alcoholic beverage industry.

Constellation Brands, one of his former career stations, owns Corona Beer and Modelo, among others. It’s one of the best-performing stocks of this bull market, up 900% since 2012!

Constellation Brands recently made huge news by acquiring a substantial position in a dominant cannabis company. It is clearly recognizing the major changes in the specialty beverages industry as well as in the CBD-infused products segment. The market is pricing exponential growth for it, as you can see from its hockey-stick shaped chart.

Companies failing to understand the CORE paradigm shift in consumer demand in recent years were punished immediately. Coca Cola, the mother of all blue-chip stocks, got slammed more than 8% in one day this earnings season. Altria Group, owner of Marlboro, is scrambling to make strategic acquisitions to offset decline in its biggest brands – which belong to the former generation’s preferences and were down 50% at one point. Kraft-Heinz, whose biggest shareholder is Warren Buffett’s company, was clobbered by 28% in one day last week.

These companies represent the Baby Boomer generation; but companies like Bai, which was acquired by Dr. Pepper, or Kevita – which was merged into PepsiCo – represent both the present and the future, with their precise marketing plans, targeting today’s consumers.

KOIOS (CSE: KBEV & US: KBEVF) is part of this elite group of cutting-edge businesses, which are catering to CURRENT consumer trends, not past ones. 

We first covered this company on the fifth of September. This was before Aussie Jiwani joined the advisory board, and well before the company rolled out its CBD-infused line of products or introduced favorable clinical studies – proving the efficiency of its proprietary line of nootropic beverages – and before retail giant, GNC Holdings, made its historic purchase order.

The share price quickly moved from CAD$0.20 (our official alert price), to an intra-day high of CAD$1.05, closing September 21^st for CAD$0.95. In that two-week period, KOIOS was the best-performing stock on the planet.

Here’s what transpired since then, though, as many small-cap companies got smacked in the December meltdown, which saw investors selling-off anything and everything:

We’re nearly back to ground zero. At CAD$0.28, we’re up 40%, but the upside potential is quite astonishing, as I asseess it. Now that GNC is stocking KOIOS products in thousands of stores, it is EXTREMELY likely to assume that competitor retailers will chase Chris Miller, the company’s CEO, with the purpose of locking-in retail agreements as well. Other retailers can’t afford seeing their customers going to GNC alone to get KOIOS products. Other retailers must consider competing with GNC for shelf space. It makes perfect sense.

There’s a snowball effect in place – I personally don’t doubt that.

Consider becoming a shareholder of KOIOS Beverage (CSE: KBEV & US: KBEVF) NOW!

KOIOS’ products are still infused with brain-enhancing nootropics; this remains a massive market that’s expected to exceed $6 billion by 2024, expanding at a CAGR of 17.9% from 2016 to 2024:

We’re now seeing Koios products practically everywhere: GNC, 7-11, Gold’s Gym, Amazon, Conoco and Wishing-U-Well – the list goes on and on.

The stock now trades for CAD$0.28. It’s nearly back to the price of our original alert; yet in the 6-month period that’s passed, it has become an official vendor of GNC, added a key individual to their advisory board, launched a line of proprietary CBD-infused products, and proved the effectiveness of its nootropic beverages on the brain. All this has been accomplished and NO DEBT on its books.

This is the reason I’m making my move immediately.

GNC’s purchase order is the starting gun. In terms of valuation, the company is 73% cheaper than it was in September, and using our internal valuation metrics, it is even more attractive than it was at CAD$0.20 on the 5^th of September – when we became the first to cover its story.

I’m in it for the long-term.

KOIOS is in a strong position to make rapid progress.

Consider Koios (CSE: KBEV & US: KBEVF) NOW!

Best Regards,

Lior Gantz
President, WealthResearchGroup.com